Multi-slice echo-planar spectroscopic MR imaging provides both global and local metabolite measures in multiple sclerosis

Magnetic Resonance in Medicine

Volumn 53, Issue 4, 2005, Pages 750-759

  Mathiesen, Henrik Kahr ^a,c   Tscherning, Thomas ^a   Sorensen, Per Soelberg ^a   Larsson, Henrik B W ^b   Rostrup, Egill ^a   Paulson, Olaf B ^a   Hanson, Lars G ^a  

^a Mental Health Services CPH   (Denmark)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Gray matter; Lesions; Multi slice echo planar spectroscopic imaging; Multiple sclerosis; Normal appearing white matter; Whole brain NAA

Indexed keywords

BIOMOLECULES; BRAIN; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; QUALITY CONTROL; SPECTROSCOPIC ANALYSIS;

ECHO-PLANAR SPECTROSCOPIC IMAGING; GRAY MATTER; LESIONS; MULTIPLE SCLEROSIS; WHITE MATTER; WHOLE BRAINS;

METABOLITES;

N ACETYLASPARTIC ACID;

ADULT; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAY MATTER; HEAD POSITION; HUMAN; INTERMETHOD COMPARISON; MALE; METABOLITE; MULTI SLICE ECHO PLANAR SPECTROSCOPIC NUCLEAR MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; WHITE MATTER; WHOLE BODY SCANNER;

EID: 16444386385     PISSN: 07403194     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrm.20407     Document Type: Article

References (40)

1. Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of the brain. Neurosci Biobehav Rev 1989;13:23-31.
2. Larsson HB, Christiansen P, Jensen M, Frederiksen J, Heltberg A, Olesen J, Henriksen O. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis. Magn Reson Med 1991;22:23-31.
3. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, Antel JP, Wolfson C, Arnold DL. Imaging axonal damage of normal appearing white matter in multiple sclerosis. Brain 1998;121:103-113.
4. Kapeller P, McLean MA, Griffin CM, Chard D, Parker GJ, Barker GJ, Thompson AJ, Miller DH. Preliminary evidence for neuronal damage in cortical gray matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopy imaging study. J Neurol 2001;248:131-138.
5. Gonen O, Catalaa I, Babb JS, Ge Y, Mannon LJ, Kolson DL, Grossman RI. Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000;54:15-19.
6. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, Matthews PM, Arnold DL. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70.
7. Tourbah A, Stievenart JL, Abanou A, Iba-Zizen MT, Hamard H, Lyon-Caen O, Cabanis EA. Normal-appearing white matter in optic neuritis and multiple sclerosis: a comparative proton spectroscopy study. Neuroradiology 1999;41:738-743.
8. Brex PA, Gomez-Anson B, Parker GJ, Molyneux PD, Miszkiel KA, Barker GJ, MacManus DG, Davie CA, Plant GT, Miller DH. Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Sci 1999;166:16-22.
9. Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A, Martinelli V, Grossman RI, Scotti G, Comi G, Falini A. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433-437.
10. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995;38:901-909.
11. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, Antel JP, Arnold DL. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998;121:1469-1477.
12. 2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2002;23:371-375.
13. Adalsteinsson E, Langer-Gould A, Homer RJ, Rao A, Sullivan EV, Lima CA, Pfefferbaum A, Atlas SW. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2003;24:1941-1945.
14. Mansfield P. Spatial mapping of the chemical shift in NMR. Magn Reson Med 1984;1:370-386.
15. Gasperini C, Paolillo A, Rovaris M, Yousry TA, Capra R, Bastianello S, Filippi M. A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis. Magn Reson Imaging 2000;18:761-763.
16. Hanson LG, Schaumburg K, Paulson OB. Reconstruction strategy for echo planar spectroscopy and its application to partially undersampled imaging. Mag Reson Med 2000;44:412-417.
17. Spielman DM, Pauly JM, Macovski A, Glover GH, Enzmann DR. Lipid-suppressed single- and multisection proton spectroscopic imaging of the human brain. J Magn Reson Imaging 1992;2:253-262.
18. Studholme C, Hawkes DJ, Hill DL. Normalized entropy measure for multimodality image alignment. In: Hanson KM, editor. Proceedings of SPIE, Vol. 3338, Medical imaging 1998: Image processing. San Diego, 1998. p 132-143.
19. Gonen O, Grossman RI. The accuracy of whole brain N-acetylaspartate quantification. Magn Reson Imaging 2000;18:1255-1258.
20. Truong TK, Clymer BD, Chakeres DW, Schmalbrock P. Three-dimensional numerical simulations of susceptibility-induced magnetic field inhomogeneities in the human head. Magn Reson Imaging 2002;20: 759-770.
21. Spielman D, Webb P, Macovski A. Water referencing for spectroscopic imaging. Magn Reson Med 1989;12:38-49.
22. Hanson LG, Adalsteinsson E, Pfefferbaum A, Spielman DM. Optimal voxel size for measuring global gray and white matter proton metabolite concentrations using chemical shift imaging. Magn Reson Med 2000;44:10-18.
23. Arnold DL, Wolinsky JS, Matthews PM, Falini A. The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64(Suppl 1): 94-101.
24. Fazekas F, Barkhof F, Filippi M, Grossman RI, Li DK, McDonald WI, McFarland HF, Paty DW, Simon JH, Wolinsky JS, Miller DH. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 1999;53:448-456.
25. Filippi M, Yousry T, Baratti C, Horsfield MA, Mammi S, Becker C, Voltz R, Spuler S, Campi A, Reiser MF, Comi G. Quantitative assessment of MRI lesion load in multiple sclerosis. A comparison of conventional spin-echo with fast fluid-attenuated inversion recovery. Brain 1996;119:1349-1355.
26. Stevenson VL, Gawne-Cain ML, Barker GJ, Thompson AJ, Miller DH. Imaging of the spinal cord and brain in multiple sclerosis: a comparative study between fast FLAIR and fast spin echo. J Neurol 1997;244: 119-124.
27. Davies SE, Newcombe J, Williams SR, McDonald WI, Clark JB. High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem 1995;64:742-748.
28. Husted CA, Goodin DS, Hugg JW, Maudsley AA, Tsuruda JS, de Bie SH, Fein G, Matson GB, Weiner MW. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 1994;36:157-165.
29. Inglese M, Li BS, Rusinek H, Babb JS, Grossman RI, Gonen O. Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 2003;50:190-195.
30. Suhy J, Rooney WD, Goodkin DE, Capizzano AA, Soher BJ, Maudsley AA, Waubant E, Andersson PB, Weiner MW. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler 2000;6:148-155.
31. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal ageing. Magn Reson Med 1999;41:276-284.
32. Christiansen P, Toft P, Larsson HB, Stubgaard M, Henriksen O. The concentration of N-acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in adulthood and senium. Magn Reson Imaging 1993;11:799-806.
33. 2 relaxation times of normal appearing white matter and lesions in multiple sclerosis. J Neurol Sci 2000;178:81-87.
34. Lai M, Hodgson T, Gawne-Cain M, Webb S, MacManus D, McDonald WI, Thompson AJ, Miller DH. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60: 339-341.
35. Miller DH. Spectrum of abnormalities in multiple sclerosis. In: Miller DH, Kesselring J, McDonald WI, Paty DW, Thompson AJ. Magnetic resonance in multiple sclerosis. Cambridge: Cambridge University Press; 1997. p 31-62.
36. Edelstein WA, Glover GH, Hardy CJ, Redington RW. The intrinsic signal-to-noise ratio in NMR imaging. Magn Reson Med 1986;3:604-618.
37. Gonen O, Viswanathan AK, Catalaa I, Babb J, Udupa J, Grossman RI. Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med 1998;40:684-689.
38. Inglese M, Ge Y, Filippi M, Falini A, Grossman RI, Gonen O. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 2004;21:1825-1829.
39. Miller DH, Thompson AJ, Filippi M. Magnetic resonance studies of abnormalities in the normal appearing white matter and gray matter in multiple sclerosis. J Neurol 2003;250:1407-1419.
40. Narayanan S, De Stefano N, Francis GS, Arnaoutelis R, Caramanos Z, Collins DL, Pelletier D, Arnason BGW, Antel JP, Arnold DL. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001;248:979-986.